Comparing Rinvoq vs Risankizumab
Rinvoq (upadacitinib) | Risankizumab |
|
---|
Rinvoq (upadacitinib) | Risankizumab |
|
|||||||
---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Crohn's Disease, Ankylosing Spondylitis, Atopic Dermatitis, Non-Radiographic Axial Spondyloarthritis, Polyarticular Juvenile Idiopathic Arthritis, Giant Cell Arteritis, Psoriatic... View more |
Prescription only
Prescribed for Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Plaque Psoriasis, Psoriasis. Risankizumab may also be used for purposes not listed in this medication guide. |
Related suggestions Ulcerative Colitis
Crohn's Disease
Popular comparisons
|
|||||||
More about Rinvoq (upadacitinib) | More about Risankizumab | ||||||||
Ratings & Reviews | |||||||||
Rinvoq has an average rating of 7.0 out of 10 from a total of 228 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 17% reported a negative effect. |
Risankizumab has an average rating of 7.9 out of 10 from a total of 65 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 12% reported a negative effect. |
||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Rinvoq side effects |
View all Risankizumab side effects |
||||||||
Drug Class | |||||||||
Generic Availability | |||||||||
N/A |
|||||||||
Pricing and Coupons * Prices are without insurance | |||||||||
View all Rinvoq prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
Dosage Forms | |||||||||
|
N/A |
||||||||
Brand Names | |||||||||
Other upadacitinib brands include: Rinvoq LQ | Skyrizi | ||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
14 hours |
672 hours |
||||||||
CSA Schedule 1 View glossary of CSA terms | |||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | |||||||||
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
Drug Interactions | |||||||||
A total of 610 drugs are known to interact with Rinvoq:
|
A total of 187 drugs are known to interact with Risankizumab:
|
||||||||
Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
Disease Interactions | |||||||||
First Approval Date | |||||||||
August 16, 2019 |
April 23, 2019 |
||||||||
WADA Class View classifications | |||||||||
N/A |
N/A |
||||||||
More Information | |||||||||
Patient Resources | |||||||||
Professional Resources | |||||||||
Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Xeljanz
Xeljanz (tofacitinib) is an oral Janus kinase (JAK) inhibitor that may be used alone or with other ...
Entyvio
Entyvio (vedolizumab) is used to treat ulcerative colitis (UC) and Crohn's disease, reducing ...
Otezla
Otezla (apremilast) is used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers ...
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Omvoh
Omvoh is used to treat moderate to severe ulcerative colitis or Crohn's disease in adults. This ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Celebrex
Celebrex is a nonsteroidal anti-inflammatory drug used to treat pain or inflammation. Learn about ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.